CEO and founder of BTB Pharma
Thomas Bäckström has extensive research experience from academia and the biopharmaceutical industry. He earned his PhD at Auckland University, New Zealand and after a couple of Post-Doctoral positions in USA and Switzerland he returned to New Zealand to set up his own research group. Thomas spent 11 years at the Malaghan Institute of Medical Research in Wellington, as a Principal Investigator, mainly working with pre-clinical models of Multiple Sclerosis.
He then returned to Scandinavia and worked as a Director of T cell Biology and Immunogenicity at Novo Nordisk, Copenhagen, Denmark for 6 years. At this time, he started his own Biotech Company, BTB Pharma. The goal is to treat or even to cure organ/tissue specific autoimmune diseases such as Multiple Sclerosis, Type I Diabetes, Rheumatoid Arthritis and Allergy.
BTB Pharma is collaborating with research scientists at Lund’s University; Biomedical Centre (BMC) in Lund, Clinical Research Centre (CRC) in Malmö and scientists in Denmark. The company is also getting ready to start it owns research activities at Lund’s University.